Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260383 | 1.00 | NFKB1 (0.36) | NFKB1NFKB2RELAHDAC1HDAC2 | |
| SCHEMBL21818968 | 0.87 | CYP1A2 (0.39) | NFKB1NFKB2RELAHDAC1HDAC2 | |
| SCHEMBL21818967 | 0.87 | CYP1A2 (0.39) | NFKB1NFKB2RELAHDAC1HDAC2 | |
| SCHEMBL2258075 | 0.86 | NFKB1 (0.36) | NFKB1NFKB2RELAHDAC1HDAC2 | |
| SCHEMBL2259282 | 0.86 | NFKB1 (0.36) | NFKB1NFKB2RELAHDAC1HDAC2 | |
| SCHEMBL2259288 | 0.86 | NFKB1 (0.36) | NFKB1NFKB2RELAHDAC1HDAC2 | |
| SCHEMBL21818876 | 0.84 | EPHX2 (0.36) | NFKB1NFKB2RELAHDAC1HDAC2 | |
| SCHEMBL21818877 | 0.84 | EPHX2 (0.36) | NFKB1NFKB2RELAHDAC1HDAC2 | |
| SCHEMBL24208061 | 0.84 | NFKB1 (0.36) | NFKB1NFKB2RELAHDAC1HDAC2 | |
| SCHEMBL8328107 | 0.83 | HDAC6 (0.36) | HDAC1HDAC2HDAC6CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242303-B2 | Method of producing optically active N-(halopropyl) amino acid derivative | NAGASE & CO., LTD. (JP) | 2012-08-14 | — | — | US | claimed |
| EP-2192110-B1 | METHOD OF PRODUCING OPTICALLY ACTIVE N-(HALOPROPYL)AMINO ACID DERIVATIVE | NAGASE & CO LTD (JP) | 2016-05-04 | — | — | EP | disclosed |
| US-8242303-B2 | Method of producing optically active N-(halopropyl) amino acid derivative | NAGASE & CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20110190527-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE N-(HALOPROPYL) AMINO ACID DERIVATIVE | NAGASE & CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190527-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE N-(HALOPROPYL) AMINO ACID DERIVATIVE | NPPA, NPEPPS, ALAD | NFKB1 1852/4885NFKB2 2056/4885RELA 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.